Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron Court Permits Government to Pursue False Certification Theory - On August 4, the district court in the closely ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

At this year's Regeneron International Science and Engineering Fair in Columbus, judges awarded the George D. Yancopoulos Innovator Award to Kovalčík, whose drug production method — as Business ...

According to Benzinga Pro, Regeneron Pharmaceuticals's peer group average for short interest as a percentage of float is 6.13 ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...

The close-knit South Shore village scored points for its strong public schools, quick commute to NYC and nearby beach access, ...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...